1.22
-0.04 (-3.17%)
| Penutupan Terdahulu | 1.26 |
| Buka | 1.27 |
| Jumlah Dagangan | 130,959 |
| Purata Dagangan (3B) | 251,298 |
| Modal Pasaran | 155,241,824 |
| Harga / Buku (P/B) | 17.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Jun 2025 - 8 Jul 2025 |
| EPS Cair (TTM) | -0.110 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.69% |
| Nisbah Semasa (MRQ) | 1.02 |
| Aliran Tunai Operasi (OCF TTM) | -1.53 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.99 M |
| Pulangan Atas Aset (ROA TTM) | -84.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -250.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Tiziana Life Sciences Ltd | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.00 |
|
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 43.06% |
| % Dimiliki oleh Institusi | 2.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Zhang Financial Llc | 31 Dec 2025 | 99,900 |
| Rachor Investment Advisory Services, Llc | 31 Dec 2025 | 17,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |